Health Care Technology

iSpecimen

iSpecimen released FY2025 Q3 earnings on November 17 (EST), actual revenue USD 106.59 K (forecast USD 3.327 M), actual EPS USD -0.4761 (forecast USD -3.8)

iSpecimen released FY2025 9 Months Earnings on November 17, 2025 (EST) with actual revenue of USD 1.877 M and EPS of USD -1.6094

iSpecimen Holds About 1 Million SOL, Currently Valued at Approximately $243.5 Million

iSpecimen released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 713.14 K (forecast USD 3.104 M), actual EPS USD -0.4199 (forecast USD -3.8)

iSpecimen released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 1.771 M, actual EPS USD -1.1224

iSpecimen Inc. revises bylaws to lower quorum requirements for shareholder meetings

Richard Paulini Resigns from iSpecimen Chairman Position

iSpecimen released FY2025 Q1 earnings on May 19 (EST), actual revenue USD 1.058 M (forecast USD 2.546 M), actual EPS USD -0.7138 (forecast USD -4.4)

iSpecimen Inc. Delays Submission of Q1 2025 Financial Report

iSpecimen released FY2024 annual earnings on April 14 (EST), actual revenue USD 9.291 M (forecast USD 11.08 M), actual EPS USD -17.5814 (forecast USD -17.6)

iSpecimen released FY2024 Q4 earnings on April 14 (EST), actual revenue USD 1.476 M (forecast USD 2.977 M), actual EPS USD -5.3448 (forecast USD -4)

iSpecimen released FY2024 9 Months Earnings on November 7, 2024 (EST), with actual revenue of 7,815,608 USD and EPS of -12.1704

iSpecimen released FY2024 Q3 earnings on November 7 (EST), actual revenue $2,661,936 (forecast $2.947M), actual EPS -2.0954 (forecast -3.8)

iSpecimen Inc announces public offering of common stock and warrants

iSpecimen Inc. Secures $1 Million Loan Agreement and Adds Three New Board Members

iSpecimen reports Q2 EPS of -$0.19 and revenue of $2.86 million

iSpecimen Inc. expects quarterly revenue to grow by 77.3% to $2.881 million

iSpecimen released FY2023 Q4 earnings on March 13 After-Market EST, actual revenue USD 2.575 M (forecast USD 3.041 M), actual EPS USD -6.7715 (forecast USD -4.8)

iSpecimen released FY2023 earnings on March 13 After-Market EST, actual revenue USD 9.928 M (forecast USD 10.39 M), actual EPS USD -24.5527 (forecast USD -22.4)

Rich Sparkle

Novabay Pharmac

Valens Semiconductor

Greenpower Motor

Alpha Tech

Offerpad Solutions

VCI Global

Tryhard

Tradr 2X Long APLD Daily ETF

ZeZentalis Pharma

Veeva Systems -CL

Doximity

Waystar

Phreesia

HealthStream

OptimizeRx

LifeMD

CareCloud

Forian

Certara

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

iSpecimen(ISPC.US)